文献速递男科与性医学

2型糖尿病长期睾酮治疗与死亡率降低相关但心血管危险因素未改善

Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
PubMed 文献 · BJU Int · 2018-10-16

该研究基于BLAST随机对照试验筛选的857例2型糖尿病男性,随访3.8年,按睾酮水平及是否接受睾酮替代治疗(TRT)分层,用Cox回归分析死亡率。结果显示TRT未改善心血管疾病(CVD)危险因素,CVD危险因素与死亡率无关;睾酮正常组和TRT组死亡率低于未治疗组,且TRT停用后死亡率降低仍存在,获益主要见于年龄>64.6岁和体重≤93.8 kg者。

要点

  • TRT未改善CVD危险因素,CVD危险因素与死亡率无关。
  • 睾酮正常组和TRT组死亡率低于未治疗组,停用TRT后仍较低。
  • 获益主要见于年龄>64.6岁和体重≤93.8 kg的男性。

核心结论

  • 正常睾酮水平和TRT相关的死亡率降低似乎不归因于所研究的CVD危险因素改善。
  • TRT在较低体重男性中影响更大,同期TRT与减重计划可能获得更好结局。

研究设计与样本

  • 研究857例2型糖尿病男性,为BLAST随机对照试验筛选人群,随访3.8年。
  • 按总睾酮(TT)>12 nmol/L且游离睾酮(FT)>0.25 nmol/L分为Group 1,TT≤12 nmol/L或FT≤0.25 nmol/L为Group 2。
  • Group 2 further分为未接受TRT(Group 2a)和接受TRT(Group 2b),Group 2b再分为停用TRT(Group 2b1)和未停用(Group 2b2)。
  • 主要结局死亡率采用Cox回归分析。

主要发现

  • TRT与CVD危险因素改善无关。
  • CVD危险因素(基线和随访期间变化)与死亡率无关。
  • 以Group 2a为参照,Group 1和Group 2b死亡率更低,即使回归模型纳入CVD危险因素。
  • 死亡率:Group 2b1为6.2%,Group 2b2为0%,Group 2a为16.9%。
  • Group 1和Group 2b的较低死亡率主要见于年龄>64.6岁和体重≤93.8 kg的男性。

关键数值与推荐

  • Group 1:TT>12 nmol/L且FT>0.25 nmol/L。
  • Group 2:TT≤12 nmol/L或FT≤0.25 nmol/L。
  • 死亡率:Group 2b1为6.2%,Group 2b2为0%,Group 2a为16.9%。
  • 获益主要见于年龄>64.6岁和体重≤93.8 kg的男性。

临床怎么用

  • 对于2型糖尿病合并睾酮缺乏的男性,TRT可能降低死亡率但不改善常规CVD危险因素。
  • TRT获益在较低体重男性中更明显,可考虑同期TRT与减重计划。
  • 停用TRT后死亡率降低仍存在,但需结合个体情况评估。

局限性

  • 研究为BLAST随机对照试验筛选人群的观察性分析,非随机比较。
  • 随访时间3.8年,长期结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To further characterize the beneficial impact of testosterone replacement therapy (TRT) on the association between mortality and hypogonadism (HG) in men with type 2 diabetes (T2DM), by determining, firstly, if changes in cardiovascular disease (CVD) risk factors after TRT play a role, secondly, whether the reduction in mortality is lost when TRT is discontinued and, finally, the presence of subgroups where benefit may be greater. MATERIALS AND METHODS: We studied 857 men with T2DM, screened for the BLAST randomized controlled trial, over 3.8 years of follow-up. The men were stratified first by testosterone levels: group 1: total testosterone (TT) >12 nmol/L and free testosterone (FT) >0.25 nmol/L; Group 2: TT ≤12 nmol/L or FT ≤0.25 nmol/L. Group 2 was further stratified into those not on TRT (Group 2a) and those on TRT (Group 2b). Group 2b was further stratified by whether TRT was discontinued (Group 2b1) or not (Group 2b2). The principal outcome, mortality, was studied using Cox regression. RESULTS: We found that TRT was not associated with improvements in CVD risk factors. CVD risk factors (baseline and changes during follow-up) were not associated with mortality. Men in Group 1 and Group 2b were found to have lower mortality (reference: Group 2a), even with CVD risk factors included in the regression models. Mortality was lower in men in Group 2b1 (6.2%) and Group 2b2 (0%) compared with those in Group 2a (16.9%). The lower mortality associated with Group 1 and Group 2b was observed primarily in older (>64.6 years) and less overweight (≤93.8 kg) men. CONCLUSIONS: The benefits associated with normal testosterone levels and TRT (even after discontinuation) do not appear to be related to improvements in the CVD risk factors studied. In view of TRT having greater impact in men of lower weight, better outcomes may be achieved with concurrent TRT and weight reduction programmes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hackett G, Cole N, Mulay A, et al. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. BJU Int. 2018. PMID: 30216622. doi:10.1111/bju.14536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。